RKDA vs OFIX

For growth investors, Orthofix Medical Inc.

(OFIX) is the stronger pick with 2. 9% revenue growth year-over-year, versus -3. 7% for Arcadia Biosciences, Inc. (RKDA). Analysts rate Orthofix Medical Inc. (OFIX) a "Hold" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Orthofix Medical Inc.

(OFIX) delivered a total return of -72. 7%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: OFIX returned -72. 0% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcadia Biosciences, Inc.

(RKDA) is the lower-risk stock at 0. 98β versus Orthofix Medical Inc. 's 1. 21β — meaning OFIX is approximately 23% more volatile than RKDA relative to the S&P 500.

By revenue growth (latest reported year), Orthofix Medical Inc.

(OFIX) is pulling ahead at 2. 9% versus -3. 7% for Arcadia Biosciences, Inc. (RKDA). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to 30. 9% for Orthofix Medical Inc.. Over a 3-year CAGR, OFIX leads at 21. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Orthofix Medical Inc.

(OFIX) is the more profitable company, earning -11. 2% net margin versus -48. 1% for Arcadia Biosciences, Inc. — meaning it keeps -11. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OFIX leads at -8. 3% versus -205. 7% for RKDA. At the gross margin level — before operating expenses — OFIX leads at 67. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcadia Biosciences, Inc.

(RKDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98)). Both have compounded well over 10 years (RKDA: -99. 9%, OFIX: -72. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RKDA (Basic Materials) and OFIX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.